두경부암의 방사선 저항성 기전 및 극복방안 연구

키워드

참고문헌 (49)

1. Xi HQ, "Aberrant expression of EphA3 in gastric carcinoma : Correlation with tumor angiogenesis and survival", J Gastroenterol, 47(7), pp.785~794 (2012)
2. Yamamoto VN, "Overcoming radioresistance in head and neck squamous cell carcinoma", Oral Oncol, 63, pp.44~51 (2016)
3. Kaidar-Person O, "Precision medicine in head and neck cancer", Drug Resist Updat, 40, pp.13~16 (2018)
4. Goldstein M, "The DNA damage response : Implications for tumor responses to radiation and chemotherapy", Annu Rev Med, 66, pp.129~143 (2015)
5. Larionova I, "Radiotherapy resistance : Identifying universal biomarkers for various human cancers", J Cancer Res Clin Oncol, 148(5), pp.1015~1031 (2022)
6. Qin CJ, "XRCC2as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy", Oncotarget, 6(31), pp.32193~32204 (2015)
7. Bhattacharya P, "Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization", Int J Radiat Biol, 94(7), pp.628~644 (2018)
8. Nam HY, "Radioresistant cancer cells can be conditioned to enter senescence by mTOR inhibition", Cancer Res, 73(14), pp.4267~4277 (2013)
9. Hill RM, "Overcoming the impact of hypoxia in driving radiotherapy resistance in head and neck squamous cell carcinoma", Cancers(Basel), 14(17), pp.4130~ (2022)
10. Jackson RK, "Overcoming radioresistance: small molecule radiosensitisers and hypoxia-activated prodrugs", Clin Oncol(R Coll Radiol), 31(5), pp.290~302 (2019)
11. Moreno Roig E, "HIF-1α and HIF-2α differently regulate the radiation sensitivity of NSCLC cells", Cells, 8(1), pp.45~ (2019)
12. Rankin EB, "Hypoxic control of metastasis", Science, 352(6282), pp.175~180 (2016)
13. Vilaplana-Lopera N, "Targeting hypoxia : Revival of old remedies", Biomolecules, 11(11), pp.1604~ (2021)
14. Stakheyeva M, "Role of the immune component of tumor microenvironment in the efficiency of cancer treatment : Perspectives for the personalized therapy", Curr Pharm Des, 23(32), pp.4807~4826 (2017)
15. Biffi G, "Diversity and biology of cancer-associated fibroblasts", Physiol Rev, 101(1), pp.147~176 (2021)
16. Chen Y, "Clinical and therapeutic relevance of cancer-associated fibroblasts", Nat Rev Clin Oncol, 18(12), pp.792~804 (2021)
17. Larionova I, "Interaction of tumor-associated macrophages and cancer chemotherapy", Oncoimmunology, 8(7), pp.1596004~ (2019)
18. Boutilier AJ, "Macrophage polarization states in the tumor microenvironment", Int J Mol Sci, 22(13), pp.6995~ (2021)
19. Lee WH, "Tristetraprolin regulates phagocytosis through interaction with CD47 in head and neck cancer", Exp Ther Med, 24(3), pp.541~ (2022)
20. Mardanshahi A, "The PI3K", AKT, Mol Biol Rep, pp.2021, 48(8)[DOI]
21. Simpson DR, "Targeting the PI3K", AKT, Oral Oncol, pp.2015, 51(4)[DOI]
22. Huo X, "Analysis of the expression level and methylation of tumor protein p53, phosphatase and tensin homolog and mutS homolog 2 in N-methyl-N-nitrosoureainduced thymic lymphoma in C57BL", 6 mice, 2017, pp.14(4), 4339~4348
23. Madsen RR, "PI3K in stemness regulation : From development to cancer", Biochem Soc Trans, 48(1), pp.301~315 (2020)
24. Massacesi C, "PI3K inhibitors as new cancer therapeutics : Implications for clinical trial design", Onco Targets Ther, 9, pp.203~210 (2016)
25. Marquard FE, "PI3K", AKT, Biochem Pharmacol, pp.2020, 172[DOI]
26. Burris HA 3rd, "Overcoming acquired resistance to anticancer therapy : Focus on the PI3K", AKT, Cancer Chemother Pharmacol, pp.2013, 71(4)[DOI]
27. Horn D, "Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma", Expert Opin Ther Targets, 19(6), pp.795~805 (2015)
28. Jiang N, "Role of PI3K", AKT pathway in cancer : The framework of malignant behavior, 2020, pp.47(6), 4587~4629
29. Han MW, "Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer", Oral Oncol, 78, pp.56~63 (2018)
30. Worby CA, "PTEN", Annu Rev Biochem, 83, pp.641~669 (2014)
31. Leslie NR, "PTEN function : How normal cells control it and tumour cells lose it", Biochem J, 382(Pt 1), pp.1~11 (2004)
32. Papa A, "The PTEN–PI3K axis in cancer", Biomolecules, 9(4), pp.153~ (2019)
33. Kim SH, "EPHA3contributes to epigenetic suppression of PTEN in radioresistant head and neck cancer", Biomolecules, 11(4), pp.599~ (2021)
34. Héroult M, "Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression", Exp Cell Res, 312(5), pp.642~650 (2006)
35. Brantley-Sieders D, "Eph receptor tyrosine kinases in tumor and tumor microenvironment", Curr Pharm Des, 10(27), pp.3431~3442 (2004)
36. Keane N, "EPHA3 as a novel therapeutic target in the hematological malignancies", Expert Rev Hematol, 5(3), pp.325~340 (2012)
37. Charmsaz S, "EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia", Leukemia, 31(8), pp.1779~1787 (2017)
38. Janes PW, "EphA3 biology and cancer", Growth Factors, 32(6), pp.176~189 (2014)
39. Kim SH, "EphA3 maintains radioresistance in head and neck cancers through epithelial mesenchymal transition", Cell Signal, 47, pp.122~130 (2018)
40. Day BW, "Eph receptors as therapeutic targets in glioblastoma", Br J Cancer, 111(7), pp.1255~1261 (2014)
41. Day BW, "EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme", Cancer Cell, 23(2), pp.238~248 (2013)
42. Vail ME, "Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment", Cancer Res, 74(16), pp.4470~4481 (2014)
43. Chang HW, "Expression of Ku80 correlates with sensitivities to radiation in cancer cell lines of the head and neck", Oral Oncol, 42(10), pp.979~986 (2006)
44. Lodola A, "Targeting Eph", ephrin system in cancer therapy, 2017, pp.142, 152~162
45. Xi HQ, "Eph receptors and ephrins as targets for cancer therapy", J Cell Mol Med, 16(12), pp.2894~2909 (2012)
46. La Rocca F, "EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells", Cell Oncol(Dordr), 40(5), pp.483~496 (2017)
47. Swords RT, "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study", Leuk Res, 50, pp.123~131 (2016)
48. Perri F, "Radioresistance in head and neck squamous cell carcinoma : Biological bases and therapeutic implications", Head Neck, 37(5), pp.763~770 (2015)
49. de Jong MC, "CD44 expression predicts local recurrence after radiotherapy in larynx cancer", Clin Cancer Res, 16(21), pp.5329~5338 (2010)

관련 논문AI추천